Vivos Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Vivos Therapeutics

15/11/2024 14:13

* Vivos Therapeutics Inc  VVOS.OQ  reported a quarterly
adjusted
loss of 40 cents​​ per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of $-1.62.  The mean expectation of two analysts
for the quarter was for a loss of 61 cents per share. 
    * Revenue rose 16.9% to $3.86 million from a year ago;
analysts
expected $4.06 million. 
    * Vivos Therapeutics Inc's reported EPS for the quarter was
a loss
of 40 cents​.
    * The company reported a quarterly loss of $2.62 million.
    * Vivos Therapeutics Inc shares had risen by 19.5% this
quarter and lost 74.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 36.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the medical
equipment,
supplies & distribution peer group is also "buy"

Wall Street's median 12-month price target for Vivos
Therapeutics Inc is 7.43 
This summary was machine generated from LSEG data November 15 at
02:13 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.61          -0.40          Beat
 Jun. 30 2024      -1.05          -0.60          Beat
 Mar. 31 2024      -1.17          -1.63          Missed
 Dec. 31 2023      -1.90          -3.05          Missed